Cart
0

Idiopathic Pulmonary Fibrosis Market by Type of Drug (Pirfenidone, Nintedanib) and Region (North America, Europe, Asia-Pacific, and LAMEA) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Get 20% Free Customization In This Report
LI_174407
Pages: 122
Sep 2017 | 2260 Views
 
Author's : Prateeksha Kaul & Pallavi Jaiswal
Tables: 60
Charts: 32
 

Idiopathic Pulmonary Fibrosis Market Overview:

Idiopathic Pulmonary Fibrosis Market was valued at $1,616million in 2016, and is estimated to reach $3,569 million by 2023, growing at a CAGR of 11.9% from 2017 to 2023. Idiopathic pulmonary fibrosis is a type of interstitial lung disease in which the lung tissues are damaged, thereby reducing its oxygen delivering capacity. Increase in incidence of fibrotic diseases poses a high risk factor for idiopathic pulmonary fibrosis.

In addition, rise in geriatric population and surge in cigarette smoking population boost the market growth. However, the real cause of the disease is unknown due to which there is unavailability of medications impedes the market growth.

Rise in Geriatric Population

Increase in the number of aging population has been witnessed worldwide. According to a WHO report, around 524 million people were above 65 years in 2010, and the number is expected to reach 1.5 billion by 2050, which is estimated to constitute about 16% of the total world population. Thus, increase in elderly individuals is expected to result in rise in incidence of lung disorders, which in turn increases the risk for idiopathic pulmonary fibrosis, thereby fueling the market growth.

Growth in Asia-Pacific

Asia-Pacific offers lucrative opportunities for the market growth, owing to presence of large pool of patients suffering from fibrotic disease. In addition, increase in efforts undertaken by various companies to launch new medications that are currently into pipeline analysis supplement the growth of the idiopathic pulmonary fibrosis market in Asia-Pacific.

Global Idiopathic Pulmonary Fibrosis Market Segmentation

Get more information on this report : Request Sample Pages

The global idiopathic pulmonary fibrosis market is segmented on the basis of type of drug and region. According to type of drug, the market is divided into pirfenidone and nintedanib. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in this market include MediciNova, Inc., Boehringer Ingelheim, F. Hoffmann-La Roche, FibroGen, Inc., Promedior, Inc., Merck & Co., Inc., Galapagos NV, Biogen, Bristol-Myers Squibb Company, Prometic Life Sciences Inc., and Cipla Inc.

South Africa Idiopathic Pulmonary Fibrosis Market, 20162023 ($million)

Get more information on this report : Request Sample Pages

Key Benefits

  • The study provides an in-depth analysis of the global idiopathic pulmonary fibrosis market with current trends and future estimations to elucidate the imminent investment pockets.
  • Quantitative analysis from 2016 to 2023 is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
  • Extensive analysis is conducted by closely following key product positioning and monitoring the top contenders within the market framework.

Idiopathic Pulmonary Fibrosis Market Key Segments:

By Type of Drug

  • Pirfenidone
  • Nintedanib

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

Chapter: 1 INTRODUCTION

1.1. KEY BENEFITS
1.2. KEY MARKET SEGMENTS
1.3. RESEARCH METHODOLOGY

1.3.1. Secondary research
1.3.2. Primary research
1.3.3. Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top winning strategies
3.2.2. Top investment pockets

3.3. MARKET SHARE ANALYSIS, 2016
3.4. MARKET DYNAMICS

3.4.1. Drivers

3.4.1.1. Growth in prevalence of fibrotic disease
3.4.1.2. Increase in geriatric population
3.4.1.3. Increase in cigarette smoking

3.4.2. Restraints

3.4.2.1. Unavailability of proper treatment options

3.4.3. Opportunities

3.4.3.1. Introduction of effective drug treatment for idiopathic pulmonary fibrosis
3.4.3.2. Emerging nations

3.4.4. Impact analyses

Chapter: 4 IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. PIRFENIDONE

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. NINTEDANIB

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

Chapter: 5 IDIOPATHIC PULMONARY FIBROSIS MARKET, BY REGION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. NORTH AMERICA

5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast
5.2.4. U.S.
5.2.5. Canada
5.2.6. Mexico

5.3. EUROPE

5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast
5.3.4. Germany
5.3.5. France
5.3.6. UK
5.3.7. Italy
5.3.8. Spain
5.3.9. Rest of Europe

5.4. ASIA-PACIFIC

5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast
5.4.4. Japan
5.4.5. China
5.4.6. India
5.4.7. South Korea
5.4.8. Rest of Asia-Pacific

5.5. LAMEA

5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast
5.5.4. Brazil
5.5.5. South Africa
5.5.6. Saudi Arabia
5.5.7. Rest of LAMEA

Chapter: 6 COMPANY PROFILES

6.1. BIOGEN, INC.

6.1.1. Company overview
6.1.2. Company snapshot
6.1.3. Operating business segments
6.1.4. Product portfolio
6.1.5. Business performance

6.2. BOEHRINGER INGELHEIM GMBH

6.2.1. Company overview
6.2.2. Operating business segment
6.2.3. Product portfolio
6.2.4. Business performance
6.2.5. Key strategic moves and developments

6.3. BRISTOL-MYERS SQUIBB COMPANY

6.3.1. Company overview
6.3.2. Company snapshot
6.3.3. Operating business segment
6.3.4. Product portfolio
6.3.5. Business performance
6.3.6. Key strategic moves and developments

6.4. CIPLA INC.

6.4.1. Company overview
6.4.2. Company snapshot
6.4.3. Operating business segments
6.4.4. Product portfolio
6.4.5. Business performance

6.5. F. HOFFMANN-LA ROCHE AG

6.5.1. Company overview
6.5.2. Company snapshot
6.5.3. Operating business segments
6.5.4. Product portfolio
6.5.5. Business performance
6.5.6. Key strategic moves and developments

6.6. FIBROGEN, INC.

6.6.1. Company overview
6.6.2. Company snapshot
6.6.3. Operating business segments
6.6.4. Product portfolio
6.6.5. Business performance

6.7. GALAPAGOS NV.

6.7.1. Company overview
6.7.2. Company snapshot
6.7.3. Operating business segments
6.7.4. Product portfolio
6.7.5. Business performance
6.7.6. Key strategic moves and developments

6.8. MEDICINOVA, INC.

6.8.1. Company overview
6.8.2. Company snapshot
6.8.3. Operating business segments
6.8.4. Product portfolio
6.8.5. Business performance

6.9. MERCK & CO., INC.

6.9.1. Company overview
6.9.2. Company snapshot
6.9.3. Operating business segments
6.9.4. Product portfolio
6.9.5. Business performance
6.9.6. Key strategic moves and developments

6.10. PROMETIC LIFE SCIENCES INC.

6.10.1. Company overview
6.10.2. Company snapshot
6.10.3. Operating business segments
6.10.4. Product portfolio
6.10.5. Business performance
6.10.6. Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 2. IDIOPATHIC PULMONARY FIBROSIS MARKET FOR PIRFENIDONE, BY REGION, 2016-2023 ($MILLION)
TABLE 3. IDIOPATHIC PULMONARY FIBROSIS MARKET FOR NINTEDANIB, BY REGION, 2016-2023 ($MILLION)
TABLE 4. IDIOPATHIC PULMONARY FIBROSIS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 5. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 6. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 7. U.S. IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 8. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 9. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 10. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 11. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 12. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 13. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 14. UK IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 15. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 16. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 17. REST OF EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 18. ASIA PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 19. ASIA PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 20. JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 21. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 22. INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 23. SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 24. REST OF ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 25. LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 26. LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 27. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 28. SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 29. SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 30. REST OF LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023 ($MILLION)
TABLE 31. BIOGEN: COMPANY SNAPSHOT
TABLE 32. BIOGEN: OPERATING SEGMENTS
TABLE 33. BIOGEN: IPF PRODUCT LINE
TABLE 34. BOEHRINGER: COMPANY SNAPSHOT
TABLE 35. BOEHINGER: OPERATING SEGMENTS
TABLE 36. BOEHINGER: IPF PRODUCT LINE
TABLE 37. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 38. BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
TABLE 39. BRISTOL-MYERS SQUIBB: IPF PRODUCT LINE
TABLE 40. CIPLA: COMPANY SNAPSHOT
TABLE 41. CIPLA: OPERATING SEGMENTS
TABLE 42. CIPLA: IPF PRODUCT LINE
TABLE 43. ROCHE: COMPANY SNAPSHOT
TABLE 44. ROCHE: OPERATING SEGMENT
TABLE 45. ROCHE: IPF PRODUCT LINE
TABLE 46. FIBROGEN: COMPANY SNAPSHOT
TABLE 47. FIBROGEN: OPERATING SEGMENTS
TABLE 48. FIBROGEN: IPF PRODUCT LINE
TABLE 49. GALAPAGOS: COMPANY SNAPSHOT
TABLE 50. GALAPAGOS: OPERATING SEGMENTS
TABLE 51. GALAPAGOS: IPF PRODUCT LINE
TABLE 52. MEDICINOVA: COMPANY SNAPSHOT
TABLE 53. MEDICINOVA: OPERATING SEGMENTS
TABLE 54. MEDICINOVA: IPF PRODUCT LINE
TABLE 55. MERCK: COMPANY SNAPSHOT
TABLE 56. MERCK: OPERATING SEGMENTS
TABLE 57. MERCK: IPF PRODUCT LINE
TABLE 58. PROMETIC: COMPANY SNAPSHOT
TABLE 59. PROMETIC: OPERATING SEGMENTS
TABLE 60. PROMEDIOR: IPF PRODUCT LINE

LIST OF FIGURES

FIGURE 1. IDIOPATHIC PULMONARY FIBROSIS MARKET SEGMENTATION
FIGURE 2. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (2016)
FIGURE 3. TOP WINNING STRATEGIES: NATURE AND TYPE, (2014-2017)
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND COMPANY, (2014-2017)
FIGURE 5. TOP INVESTMENT POCKETS
FIGURE 6. MARKET SHARE ANALYSIS, 2016
FIGURE 7. IMPACT ANALYSES, 2016
FIGURE 8. BIOGEN: NET SALES, 2014-2016 ($MILLION)
FIGURE 9. BIOGEN: REVENUE SHARE BY SEGMENT 2016 (%)
FIGURE 10. BIOGEN: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 11. BOEHINGER: NET SALES, 2014-2016 ($MILLION)
FIGURE 12. BOEHRINGER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 13. BOEHRINGER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 14. BRISTOL-MYERS SQUIBB: REVENUE, 2014-2016 ($MILLION)
FIGURE 15. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 16. BRISTOL-MYERS SQUIBB: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 17. CIPLA: NET SALES, 2015-2017 ($MILLION)
FIGURE 18. CIPLA: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 19. CIPLA: REVENUE BY GEOGRAPHY, 2017 (%)
FIGURE 20. ROCHE: REVENUE, 2014-2016 ($MILLION)
FIGURE 21. ROCHE: REVENUE BY SEGMENT, 2016 (%)
FIGURE 22. ROCHE: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 23. FIBROGEN: NET-SALES, 2014-2016 ($MILLION)
FIGURE 24. FIBROGEN: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 25. GALAPAGOS: NET SALES, 2014-2016 ($MILLION)
FIGURE 26. GALAPAGOS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 27. GALAPAGOS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 28. MERCK: NET SALES, 2014-2016 ($MILLION)
FIGURE 29. MERCK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 30. MERCK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 31. PROMETIC: NET SALES, 2014-2016 ($MILLION)
FIGURE 32. PROMETIC: REVENUE BY GEOGRAPHY, 2016 (%)

 

Globally, IPF, a common lung disease in which tissues in the lungs become thick, thus restricting the flow of oxygen in the blood stream, constitute a major proportion of health and economic burden. Hence, availability of advanced treatment options for IPF is a vital option to help preserve lung function.

Upsurge in the incidence of population of smokers and rise in geriatric population increase the risk for idiopathic pulmonary fibrosis, which in turn boost the market growth. Moreover, people with symptoms of gastroesophageal reflux disease possess the risk of IPF, which is propels the growth of the market.

Asia-Pacific is expected to offer lucrative opportunities for the market due to rapid increase in geriatric population and rise in cigarette smoking population. Thus, emerging countries, such as China and India, possess high growth potential.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
Idiopathic Pulmonary Fibrosis Market- Global Opportunity Analysis and Industry Forecast, 2017-2023

  • Online Only
  • $3456
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $8995
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo